← Back to Discover
NEA Management Company, LLC
Period ended Jun 30, 2026 · Latest filing Aug 14, 2026
These quarterly holdings are delayed and may not include all assets or short positions.
Values are from the reporting date, not current prices or purchase costs.
The same security may appear in multiple rows.
Source: SEC
Reported portfolio value
Quarter-end reported holdings; not current value or investment performance.
View reported values
- Jun 30, 2026: $1,587,937,058
More quarters will appear as history becomes available.
Top holdings
Top 10 at Jun 30, 2026. Matching entries are combined; security classes and options remain separate. Shares exclude principal amounts; option shares reflect the reported underlying amount.
View top holdings values
- Trevi Therapeutics, Inc. · COM · 89532M101 · shares: $246,594,552
- MBX Biosciences, Inc. · COM · 55287L101 · shares: $199,519,627
- Monte Rosa Therapeutics, Inc. · COM · 61225M102 · shares: $186,153,612
- Celcuity Inc. · COM · 15102K100 · shares: $178,958,892
- Spyglass Pharma, Inc. · COM SHS · 85220G109 · shares: $164,552,620
- Savara, Inc. · COM · 805111101 · shares: $150,742,986
- Zenas BioPharma, Inc. · COM · 98937L105 · shares: $102,109,298
- Coursera, Inc. · COM · 22266M104 · shares: $72,574,217
- Aurinia Pharmaceuticals, Inc. · COM · 05156V102 · shares: $67,368,083
- CRISPR Therapeutics AG · NAMEN AKT · H17182108 · shares: $57,734,408
Reported holdings
26 reported entries| Issuer | Class | CUSIP | Type | Shares / principal | Reported value (USD) |
|---|---|---|---|---|---|
| Trevi Therapeutics, Inc. | COM | 89532M101 | — | 13,222,228 shares | $246,594,552 |
| MBX Biosciences, Inc. | COM | 55287L101 | — | 3,614,486 shares | $199,519,627 |
| Monte Rosa Therapeutics, Inc. | COM | 61225M102 | — | 7,692,298 shares | $186,153,612 |
| Celcuity Inc. | COM | 15102K100 | — | 1,710,561 shares | $178,958,892 |
| Spyglass Pharma, Inc. | COM SHS | 85220G109 | — | 7,392,301 shares | $164,552,620 |
| Savara, Inc. | COM | 805111101 | — | 24,471,264 shares | $150,742,986 |
| Zenas BioPharma, Inc. | COM | 98937L105 | — | 4,023,219 shares | $102,109,298 |
| Coursera, Inc. | COM | 22266M104 | — | 12,867,769 shares | $72,574,217 |
| Aurinia Pharmaceuticals, Inc. | COM | 05156V102 | — | 3,969,834 shares | $67,368,083 |
| CRISPR Therapeutics AG | NAMEN AKT | H17182108 | — | 1,058,570 shares | $57,734,408 |
| ORIC Pharmaceuticals, Inc. | COM | 68622P109 | — | 4,118,621 shares | $44,604,665 |
| Phathom Pharmaceuticals, Inc. | COM | 71722W107 | — | 1,960,169 shares | $21,267,834 |
| Korro Bio, Inc. | COM | 500946108 | — | 1,297,893 shares | $17,106,230 |
| X4 Pharmaceuticals, Inc. | COM | 98420X103 | — | 3,233,743 shares | $15,101,580 |
| Champions Oncology, Inc. | COM NEW | 15870P307 | — | 1,713,720 shares | $10,556,515 |
| Nkarta, Inc. | COM | 65487U108 | — | 3,568,781 shares | $10,099,650 |
| CVRx, Inc. | COM | 126638105 | — | 1,954,440 shares | $10,045,822 |
| Black Diamond Therapeutics, Inc. | COM | 09203E105 | — | 4,448,757 shares | $8,230,200 |
| Karyopharm Therapeutics Inc. | COM NEW | 48576U205 | — | 576,780 shares | $5,635,141 |
| Inventiva SA | ADS | 46124U107 | — | 1,462,586 shares | $5,528,575 |
| LeonaBio, Inc. | COM | 04746L203 | — | 464,398 shares | $4,267,818 |
| Senti Biosciences, Inc. | COM NEW | 81726A209 | — | 3,775,615 shares | $4,153,177 |
| Marker Therapeutics, Inc. | COM NEW | 57055L206 | — | 1,625,678 shares | $2,389,747 |
| OnKure Therapeutics, Inc. | COM CL A | 68277Q105 | — | 478,548 shares | $2,182,179 |
| ImageneBio, Inc. | COM | 45175G207 | — | 50,005 shares | $295,030 |
| Gossamer Bio, Inc. | COM | 38341P102 | — | 1,000,000 shares | $164,600 |